Organogenesis (Nasdaq: ORGO) will report first quarter fiscal 2026 results after market close on May 7, 2026. Management will host a conference call and live webcast at 5:00 p.m. Eastern Time the same day to discuss results and provide a corporate update with Q&A.
The live webcast is accessible via the company investor website and will be archived for approximately one year.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
This announcement sets the schedule for Organogenesis’s Q1 FY2026 results on May 7, 2026, with a con...
Analysis
This announcement sets the schedule for Organogenesis’s Q1 FY2026 results on May 7, 2026, with a conference call at 5:00 p.m. ET and a webcast archived for about one year. Investors can contextualize this upcoming report against record FY2025 net product revenue of $563.0M, solid profitability, and fiscal 2026 revenue guidance of $350M–$420M. Attention will focus on how Q1 trends align with that outlook and ongoing regulatory progress for ReNu.
Key Figures
Current Price:$2.24FY2025 Net Product Revenue:$563.0MQ4 2025 Net Product Revenue:$225.1M+5 more
8 metrics
Current Price$2.24Pre-news close level vs 52-week range
FY2025 Net Product Revenue$563.0MFull year 2025 results
Q4 2025 Net Product Revenue$225.1MQ4 2025 vs Q4 2024 +78%
FY2025 Net Income$37.0MFull year 2025
Q4 2025 Net Income$43.7MFourth quarter 2025
FY2025 Adjusted EBITDA$98.1MFull year 2025
Cash Balance$94.3MAs of Dec 31, 2025; no outstanding debt
2026 Revenue Guidance$350M–$420MFiscal 2026 total net revenue outlook with expected near-term decline
Announced timing for Q4 and FY2025 results with call and webcast details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Prior earnings date news for ORGO led to a small positive move, suggesting these scheduling updates have historically had limited price impact.
Recent Company History
Over the last several months, Organogenesis reported record FY2025 results with net product revenue of $563.0M and strong Q4 revenue of $225.1M, alongside positive net income and EBITDA. It also advanced regulatory efforts for ReNu via a rolling BLA submission. For earnings-related timing, the prior Feb 19, 2026 earnings date announcement saw only a modest 0.25% move, framing today’s Q1 FY2026 reporting date as a routine update within this broader trajectory.
Key Terms
biologics license application, rolling submission, rmat designation, tax-withholding disposition, +1 more
5 terms
biologics license applicationregulatory
"has initiated a rolling submission of a Biologics License Application (BLA) to the FDA"
A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.
rolling submissionregulatory
"has initiated a rolling submission of a Biologics License Application (BLA)"
A rolling submission is a regulatory filing process where a company sends portions of its application to health authorities as each section is completed, rather than waiting to submit the entire package at once. For investors, this can shorten the time to review and potential approval and reduces the risk of a single big setback—think of it like mailing chapters of a manuscript to an editor as they’re finished so feedback and progress happen sooner.
rmat designationregulatory
"extensive commercial history, and RMAT designation—was considered appropriate for BLA submission"
A Regenerative Medicine Advanced Therapy (RMAT) designation is a US regulatory status granted by the Food and Drug Administration to experimental cell, gene or tissue-based therapies that treat serious conditions. It gives the developer extra access to regulators and opportunities for faster review, similar to getting a fast-track lane at a government agency; for investors, RMAT can shorten time to market and reduce regulatory risk, which may increase a program’s commercial value and stock impact.
tax-withholding dispositionfinancial
"shows an award acquisition of 49,102 shares at $0.00 and a tax-withholding disposition"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
performance share awardfinancial
"shares of Class A common stock as a grant or award at $0.00 per share"
A performance share award is a type of executive or employee pay that grants company stock only if predefined performance goals are met over a set period. Think of it as a bonus paid in shares—similar to a savings payout that arrives only if certain targets are hit—so it aligns management incentives with company results and can affect future share count and shareholder value. Investors watch these awards because they influence executive behavior, potential dilution of shares, and signals about expected performance.
CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that first quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, May 7th.
Management will host a conference call at 5:00 p.m. Eastern Time on May 7th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
About Organogenesis Holdings Inc. Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.
Investor Inquiries:
ICR Healthcare
Mike Piccinino, CFA
OrganoIR@icrinc.com
Press and Media Inquiries:
Organogenesis
communications@organo.com
FAQ
When will Organogenesis (ORGO) release its Q1 2026 financial results?
Organogenesis will release Q1 fiscal 2026 results after market close on May 7, 2026. According to Organogenesis, management will discuss results and provide a corporate update during a conference call and webcast at 5:00 p.m. ET that same day.
How can investors join the Organogenesis (ORGO) May 7, 2026 earnings call and webcast?
Investors may join the live webcast via the company investor website or access the teleconference through provided links. According to Organogenesis, the webcast will be available live and archived on the investor site for about one year for later replay.
What time is the Organogenesis (ORGO) conference call on May 7, 2026 and what will it cover?
The conference call is scheduled for 5:00 p.m. Eastern Time on May 7, 2026 and will cover Q1 results and a corporate update. According to Organogenesis, management will include a question-and-answer session for investors and analysts.
Will Organogenesis (ORGO) provide a replay of the May 7, 2026 webcast?
Yes, the webcast will be archived on the company investor website for approximately one year after the live event. According to Organogenesis, investors can access the archived webcast via investors.organogenesis.com for later review.
What topics should investors expect during Organogenesis (ORGO)’s May 7, 2026 call?
Investors should expect discussion of first quarter fiscal 2026 financial results, a corporate update, and a Q&A session with management. According to Organogenesis, the call is intended to explain results and provide investor-facing commentary on company developments.
